{"DataElement":{"publicId":"3395752","version":"1","preferredName":"Sulindac Pills Remaining Pills Remaining Count","preferredDefinition":"Total number of Sulindac/placebo pills remaining.","longName":"3395748v1.0:2188893v1.0","context":"SWOG","contextVersion":"1","DataElementConcept":{"publicId":"3395748","version":"1","preferredName":"Sulindac Pills Remaining","preferredDefinition":"Sulindac/placebo pills remaining.","longName":"3395722v1.0:2177410v1.0","context":"SWOG","contextVersion":"1","ObjectClass":{"publicId":"3395722","version":"1","preferredName":"Sulindac Pills","preferredDefinition":"A sulfinylindene derivative prodrug with potential antineoplastic activity. Converted in vivo to an active metabolite, sulindac, a nonsteroidal anti-inflammatory drug (NSAID), blocks cyclic guanosine monophosphate-phosphodiesterase (cGMP-PDE), an enzyme that inhibits the normal apoptosis signal pathway; this inhibition permits the apoptotic signal pathway to proceed unopposed, resulting in apoptotic cell death. (NCI04):A dose of medicine in the form of a small pellet.","longName":"C850:C25394","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sulindac","conceptCode":"C850","definition":"A sulfinylindene derivative prodrug with potential antineoplastic activity. Converted in vivo to an active metabolite, sulindac, a nonsteroidal anti-inflammatory drug (NSAID), blocks cyclic guanosine monophosphate-phosphodiesterase (cGMP-PDE), an enzyme that inhibits the normal apoptosis signal pathway; this inhibition permits the apoptotic signal pathway to proceed unopposed, resulting in apoptotic cell death. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Pill Dosage Form","conceptCode":"C25394","definition":"A solid composed of a small, round object composed of active and/or inert ingredient(s).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA223546-572D-9D8F-E040-BB89AD434EF7","latestVersionIndicator":"Yes","beginDate":"2012-02-29","endDate":null,"createdBy":"SMITHA","dateCreated":"2012-02-29","modifiedBy":"ONEDATA","dateModified":"2012-02-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2433945","version":"1","preferredName":"Remaining","preferredDefinition":"Remaining; enduring or persisting.","longName":"C25649","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Remaining","conceptCode":"C25649","definition":"Enduring or persisting; residual, left over or behind.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"06674CCB-CDFD-04A9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-28","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-11-28","modifiedBy":"ONEDATA","dateModified":"2005-11-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA228405-D2DC-608B-E040-BB89AD432912","latestVersionIndicator":"Yes","beginDate":"2012-02-29","endDate":null,"createdBy":"SMITHA","dateCreated":"2012-02-29","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"5/16/13 jc moved to SWOG context.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2188893","version":"1","preferredName":"Pills Remaining Count","preferredDefinition":"the numeric count of tablets remaining.","longName":"PILLS_RMNG_NUM","context":"CTEP","contextVersion":"2.31","type":"Non-enumerated","dataType":"NUMBER","minLength":null,"maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2261845","version":"1","preferredName":"Count","preferredDefinition":"To determine the number or amount of something; the result of this activity.","longName":"C25463","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Count","conceptCode":"C25463","definition":"Determining the number or amount of something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"FBB87F7A-646B-1AFC-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-13","modifiedBy":"ONEDATA","dateModified":"2005-07-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CALGB CRF:Cancer and Leukemia Group B Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E5B67FF1-49F1-3D18-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-10-05","endDate":null,"createdBy":"SHIDED","dateCreated":"2004-10-05","modifiedBy":"CAMPBELB","dateModified":"2008-03-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811963","version":"1","longName":"Treatment","context":"CTEP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Total number of sulindac/plac","type":"Preferred Question Text","description":"Total number of sulindac/placebo pills participant brought in to the current visit","url":null,"context":"SWOG"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA228405-D2ED-608B-E040-BB89AD432912","latestVersionIndicator":"Yes","beginDate":"2012-02-29","endDate":null,"createdBy":"SMITHA","dateCreated":"2012-02-29","modifiedBy":"SCOTTM","dateModified":"2013-11-07","changeDescription":"5/16/13 jc moved to SWOG context.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}